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Although hemoglobin S (HbS) and hemoglobin C (HbC) are well known to protect against severe Plasmodium
falciparummalaria, conclusive evidence on their role against infection has not yet been obtained. Here we show,
in 2 populations from Burkina Faso (2007–2008), that HbS is associated with a 70% reduction of harboring
P. falciparum parasitemia at the heterozygous state (odds ratio [OR] for AS vs AA, 0.27; 95% conﬁdence interval
[CI], .11–.66; P = .004). There is no evidence of protection for HbC in the heterozygous state (OR for AC vs AA,
1.49; 95% CI, .69–3.21; P = .31), whereas protection even higher than that observed with AS is observed in the
homozygous and double heterozygous states (OR for CC + SC vs AA, 0.04; 95% CI, .01–.29; P = .002). The ab-
normal display of parasite-adhesive molecules on the surface of HbS and HbC infected erythrocytes, disrupting
the pathogenic process of sequestration, might displace the parasite from the deep to the peripheral circulation,
promoting its elimination at the spleen level.
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Sickle hemoglobin (hemoglobin S [HbS]) results from
a single-nucleotide polymorphism (SNP; rs334) of
the HBB gene encoding the β-globin chain, leading
to an aminoacidic substitution from glutamic acid to
valine (sixth codon: GAG→ GTG). Individuals with
the SS genotype have sickle cell anemia, a highly lethal
condition [1].
Nevertheless, HbS maintains a high frequency in
sub-Saharan Africa, probably owing to the survival ad-
vantage against malaria of individuals with the AS ge-
notype. There is much epidemiological evidence that
HbS protects against severe [2–8] and uncomplicated
[9–12] Plasmodium falciparum malaria in heterozygosis.
Furthermore, multiple studies have shown lower parasite
densities during symptomatic malaria in subjects with
the AS genotype than for those with AA [13–15]. Simi-
lar evidence is not available for protection against infec-
tion. A systematic review [16] pointed out that the role
of the AS genotype on P. falciparum infection has been
investigated mainly through single cross-sectional sur-
veys of the prevalence of parasitemia, yielding conﬂict-
ing results. Some studies found reduced prevalence in
subjects with AS compared with AA [17–20], but others
showed a similar [21–30] or even an increased preva-
lence [31, 32].The review [16] found only 2 longitudinal
studies of the incidence of parasitemia [33, 34], reporting
similar rates in subjects with AA and those with AS.
More recently, however, a longitudinal studyconducted in
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Uganda showed that children with the AS genotype had a
lower number of new strains detected per person-year than
those with the AA genotype and that the effect of HbS was
greater in older children [35]. A second longitudinal study con-
ducted in Mali showed that children with the AS genotype re-
mained smear-negative for a longer time than those with the
AA genotype [36].
Hemoglobin C (HbC) results from a SNP (rs33930165) of the
HBB gene leading to an aminoacidic substitution from glutamic
acid to lysine (sixth codon: GAG→AAG). Individuals with the
AC genotype are asymptomatic, those with the CC genotype
have mild hemolytic anemia, and SC double heterozygotes
have moderate sickle cell disease [1].
HbC is known to protect against severe malaria in an additive
way, with CC homozygotes showing a much higher degree of
protection than subjects with the AC genotype [2, 3, 6, 8].
There is not as much evidence of protection conferred by HbC
against uncomplicated malaria: CC homozygotes shows protec-
tion in 1 study [2], and subjects with AC show protection in case-
control [2, 37] but not perspective studies [11, 12]. The role of
HbC in parasitemia has been addressed by 6 cross-sectional
studies [21, 23, 25, 31, 38] and 1 longitudinal study [12], none
of which provided evidence for protection in subjects with the
AC genotype [16]. A reduced prevalence of P. falciparum infec-
tion was observed in subjects with CC or SC genotypes in only 1
cross-sectional study conducted in Ghana [25], but differences
did not reach statistical signiﬁcance.
Our study aimed to provide new insights into the protective
role of HbS and HbC against P. falciparum infection. We con-
ducted 5 cross-sectional surveys in rural villages of Burkina Faso
inhabited by the Fulani, Mossi, and Rimaibe communities. The
Fulani were reported elsewhere to be less infected with P. falcip-
arum and to have a different genetic background from their
neighbors, whereas the Mossi and Rimaibe show comparable
susceptibility to infection, are genetically similar [39, 40], and
will be thus grouped together as non-Fulani.
METHODS
Ethics Statement
The study received approval from the ethical committees of the
Ministry of Health of Burkina Faso and the University of Ox-
ford. Study subjects or their guardians gave written informed
consent for participation.
Study Area and Populations
The study was carried out in 4 rural villages of Burkina Faso,
northeast (Barkoumbilen and Barkoundouba) and east (Bassy and
Zanga) of Ouagadougou. Malaria transmission is hyperendemic
and seasonal, with a rainy season from June to October. The en-
tomological inoculation rates, estimated at about 100–200 infec-
tive bites per person per year, are similar across villages [39].
Study Design and Epidemiological Surveys
The study had a repeated cross-sectional design: 5 surveys were
carried out, at the beginning (August) and end (November/
December) of the 2007 and 2008 high malaria transmission sea-
sons and in the middle of the intervening dry low transmission
season (March 2008). For each survey a team of physicians exam-
ined participants for clinical signs, measured axillary body tem-
perature, and prepared blood slides for malaria diagnosis from
ﬁnger pricks. Subjects exhibiting fever (temperature, ≥37.5°C)
were treated presumptively with artemether-lumefantrine (Coar-
tem) according to manufacturer’s dosage recommendations. No
treatment was offered to carriers of asymptomatic parasitemia.
During the ﬁrst survey when a subject entered the study, a 2-
mL venous blood sample was collected in ethylenediaminetetra-
acetic acid tubes for DNA extraction.
Parasitological Diagnosis
Plasmodium falciparum asexual parasitemia was microscopical-
ly diagnosed. Blood slides with thick and thin blood smears
were prepared and stained with Giemsa stain according to stan-
dard procedures and read independently by 2 skilled microsco-
pists. The Plasmodium species was identiﬁed on the thin blood
smear. Readers examined 100 microscopic ﬁelds (correspond-
ing to 0.25 µL of blood) from the thick blood smear, parasite
counts were converted to numbers of parasites per microliter
of blood (assuming a standard count of 8000/μL), and the
mean density from 2 readings was used. A third reader was
involved when the 2 readers disagreed about positivity or
when estimated densities differed by >30%. In these cases, the
mean of the 2 closest density readings was used.
Microscopic diagnosis was conﬁrmed on DNA samples by
polymerase chain reaction ampliﬁcation of P. falciparum
EBA175 and TRAP sequences (Supplementary Methods).
Across all surveys, P. falciparum accounted for 91.4% of malaria
infections, followed by P. malariae (2.1%) and P. ovale (0.2%);
6.3% were mixed infections. Of the P. falciparum infections,
4.5% were symptomatic (parasitemia associated with fever).
DNA Extraction and HBB Genotyping
Genomic DNA was extracted from whole blood using the Nu-
cleon BACC2 Kit. The rs334 (A→HbA/T→ HbS) and
rs33930165 (G→ HbA /A→HbC) SNPs at the HBB locus
were genotyped using the Sequenom MassArray System [41].
Genotypes at the 2 SNPs were combined to obtain the HBB
genotypes: HbAA (AA + GG), HbAC (AA + AG), HbAS
(AT + GG), HbCC (AA + AA), HbSC (AT + AG), and HbSS
(TT + GG). Polymerase chain reaction [42] and sequencing
(BMR Genomics) were used to validate genotype calls for the
rare genotypes CC, SC, and SS (expected frequency, <1%).
The genotyping assays had 97% and 98% success rates respec-
tively, resulting in a complete HBB genotype for 95% of
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recruited subjects. Genotypes were in Hardy–Weinberg equilib-
rium within each population.
Statistical Analysis
Statistical analysis was conducted both at the single survey level
as well as longitudinally, and outcome data were compared be-
tween subjects with AC, AS, CC, SC, and AA (reference) geno-
types. At each of the 5 cross-sectional surveys (n = 1162,
n = 1595, n = 1281, n = 1554, and n = 1524, respectively), we
compared the prevalence of asymptomatic parasitemia. In lon-
gitudinal analyses we included all infection events, regardless of
whether or not parasitemia was associated with fever. Among
subjects who participated in all surveys (n = 481), we compared
the proportion infected at least once, the total number of infec-
tions, and the mean parasite density over 5 measurements. Fi-
nally, starting from the ﬁrst survey (n = 1162), we compared the
proportion of subjects who remained uninfected over the 5
measurements.
Prevalences were compared using a maximum likelihood es-
timate of the odds ratios (ORs) and 95% conﬁdence intervals
(CIs) within each ethnic group and a Mantel–Haenszel χ2 test
stratifying by ethnicity in the overall population. The propor-
tions of individuals infected at least once were compared
using logistic regression, the numbers of infections using Pois-
son regression, and the mean parasite densities using linear re-
gression after logarithmic transformation. The proportions of
subjects who remain uninfected over time were compared
using survival analysis based on lifetime tables and log-rank
test for the equality of survival functions, and the cumulative
probabilities of infection were compared using Poisson regres-
sion. All regression models included age (in years) as a covari-
ate. Ethnicity (Fulani or non-Fulani group) was included as a
covariate when the analysis was conducted in the overall popu-
lation. Two-sided P values were reported, with differences con-
sidered signiﬁcant at P≤ .05. All analyses were carried out with
the statistical software package Stata/IC 10.0 (StataCorp LP,
College Station, Texas).
RESULTS
Frequencies of HbS and HbC
The study included a total of 2206 subjects. The frequencies of
HbS and HbC (Table 1) are consistent with previous data in the
study populations [2, 43]. The frequency of HbS was 4%, irre-
spectively of ethnicity, sex, or age group, and the frequency of
HbC was lower in Fulani (5%) than in non-Fulani (12%), as re-
ported elsewhere [43]. Because ethnicity [39] and age [44] play a
major role in immunity to infection, we adjusted all genotype-
phenotype association analyses for these 2 factors.
Proportion of P. falciparum–Positive Slides
During 5 surveys conducted from August 2007 to December
2008, we performed 7008 microscopic diagnoses of malaria in
asymptomatic subjects (2792 in Fulani and 4216 in non-Fulani
subjects). The percentage of P. falciparum–positive slides varied
according to HBB genotype: compared with that for subjects
with the AA genotype, percentages were lower for subjects
with the AS, CC, or SC genotype, in both ethnic groups, where-
as for subjects with the AC genotype the percentage was similar
(non-Fulani) or even higher (Fulani) than for AA (Table 2).
Cross-sectional Analysis: Prevalence of Asymptomatic
P. falciparum Parasitemia
We therefore stratiﬁed the sample by survey to investigate the
association of HbS and HbC with the prevalence of P. falcipa-
rum asymptomatic infection. The results of the statistical
Table 1. Characteristics of Study Subjects and Frequency of HbS and HbC
Factor
Subjects by HBB Genotype, No. Frequency (95% CI)
AA AC AS CC SC Total HbS HbC
Ethnicity
Fulani 708 80 80 0 2 870 0.05 (.03–.06) 0.05 (.03–.06)
Non-Fulani 930 282 98 15 11 1336 0.04 (.03–.05) 0.12 (.10–.14)
Sex
Male 722 166 84 6 6 984 0.05 (.03–.06) 0.09 (.08–.11)
Female 916 196 94 9 7 1222 0.04 (.03–.05) 0.09 (.07–.11)
Age group, ya
≤5 321 71 30 4 1 427 0.04 (.02–.06) 0.09 (.07–.12)
>5 ≤ 10 319 64 27 3 2 415 0.03 (.02–.05) 0.09 (.06–.11)
>10 ≤ 20 449 100 53 4 6 612 0.05 (.03–.07) 0.09 (.07–.12)
>20 549 127 68 4 4 752 0.05 (.03–.06) 0.09 (.07–.11)
Total 1638 362 178 15 13 2206 0.04 (.04–.05) 0.09 (.08–.10)
Abbreviations: CI, confidence interval; HbC, hemoglobin C; HbS, hemoglobin S.
a Based on age at the first survey.
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comparison among HBB genotypes are shown in Table 3. The
data do not convey any consistent pattern of association with
prevalence of infection across surveys or populations. Indeed,
in both Fulani and non-Fulani groups, the AC genotype, com-
pared with the wild-type AA genotype, shows similar preva-
lences (OR ≈ 1) in some surveys and even higher prevalences
(OR > 1) in others (difference close to signiﬁcance in the overall
population for the fourth survey). On the contrary, in both pop-
ulations the AS genotype shows similar prevalences in some
surveys but lower prevalences (OR < 1) in others (signiﬁcant
difference in the overall population for the ﬁrst and ﬁfth sur-
veys). The CC genotype is present only in the non-Fulani
group and shows similar prevalences in some surveys and
lower prevalences (OR << 1) in others, although the difference
never reached statistical signiﬁcance. Finally, for surveys in
which comparison was possible in both populations, the SC ge-
notype showed lower prevalences (OR << 1) than the AA geno-
type (signiﬁcant difference in the overall population for the
fourth survey).
Table 2. Proportion of Plasmodium falciparum–Positive Blood
Slides According to HBB Genotype
HBB
Genotype by
Ethnicity
Subjects, No.
P. falciparum
Positive, %
P. falciparum
Negative
P. falciparum
Positive Total
Fulani
AA 1734 530 2264 23.4
AC 183 76 259 29.3
AS 209 55 264 20.8
SC 4 1 5 20.0
Total 2130 662 2792 23.7
Non-Fulani
AA 1566 1386 2952 47.0
AC 489 425 914 46.5
AS 159 103 262 39.3
CC 29 20 49 40.8
SC 30 9 39 23.1
Total 2273 1943 4216 46.1
Table 3. Statistical Comparison of the Prevalence of P. falciparum Asymptomatic Infection According to HBB Genotype at Each of 5
Cross-sectional Surveys
HBB
Genotype
by Survey
Fulani Non-Fulani Overall
OR (95% CI) P Valuea OR (95% CI) P Valuea OR (95% CI) P Valueb
AC
1 1.06 (.58–1.92) .85 0.87 (.61–1.23) .43 0.91 (.68–1.24) .56
2 1.44 (.79–2.62) .23 0.90 (.65–1.24) .52 0.99 (.75–1.32) .97
3 1.27 (.56–2.84) .56 0.83 (.54–1.27) .39 0.90 (.62–1.31) .59
4 1.73 (.94–3.20) .94 1.23 (.89–1.71) .89 1.32 (.99–1.76) .06
5 1.15 (.58–2.27) .70 1.03 (.75–1.42) .87 1.05 (.78–1.40) .75
AS
1 0.48 (.21–1.09) .07 0.51 (.26–1.00) .05 0.50 (.29–.84) .01
2 0.87 (.47–1.61) .66 1.13 (.68–1.87) .63 1.02 (.69–1.50) .93
3 1.33 (.59–2.99) .49 1.03 (1.53–1.99) .93 1.14 (.68–1.89) .63
4 1.12 (.61–2.08) .71 0.64 (.36–1.13) .12 0.83 (.54–1.25) .37
5 0.85 (.43–1.70) .65 0.52 (.29–.95) .03 0.64 (.41–1.01) .05
CC
1 . . . . . . 1.17 (.19–7.06) .86 . . . . . .
2 . . . . . . 0.45 (.14–1.47) .17 . . . . . .
3 . . . . . . 1.13 (.29–4.32) .86 . . . . . .
4 . . . . . . 1.18 (.37–3.75) .78 . . . . . .
5 . . . . . . 0.57 (.14–2.30) .42 . . . . . .
SC
1 1.61 (.10–26.17) .73 0.19 (.02–1.77) .10 0.40 (.09–1.88) .23
2 . . . 0.50 (.12–2.03) .33 . . . . . .
3 . . . 1.00 (.20–5.04) >.99 . . . . . .
4 0.00 (Nc) .55 0.09 (.01–.75) .01 0.09 (.01–.73) .00
5 0.00 (Nc) .46 0.46 (.09–2.37) .34 0.39 (.07–2.02) .24
“. . .” indicates there were no CC subjects in the Fulani ethnic group.
Abbreviations: CI, confidence interval; Nc, not computed; OR, odds ratio.
a Maximum likelihood estimation of the OR.
b P values determined with Mantel–Haenszel χ2 test.
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Longitudinal Analysis of Repeated Cross-sectional Data: Odds
of P. falciparum Infection, Number of Infections, and Mean
Parasite Counts Over 5 Measurements
The prevalence of P. falciparum parasitemia at a given moment
in a given population can vary with the measurement itself as
well as with many environmental (eg, transmission level) or
parasite (eg, strains with different abilities to establish infection)
factors other than host factors. Therefore, it might not be the
most appropriate phenotype to evaluate the role of human ge-
netic variants in protection from infection, which is why we
used what we believe to be a more robust phenotype indicating
susceptibility/resistance: the odds of being infected with P. fal-
ciparum at least once during 5 surveys.
We included in the analysis individuals included in all 5 sur-
veys (n = 481). We deﬁned as not infected those subjects who
never had a diagnosis of P. falciparum parasitemia, and as in-
fected those who had P. falciparum parasitemia diagnosed at
least once (Table 4). In both the Fulani (n = 186) and non-
Fulani (n = 295) groups, we observed that the odds of infection
for subjects with the AC genotype is comparable to that for
those with AA (OR in the overall population, 1.49; 95% CI,
.69–3.21; P = .31). This is not the case for subjects with AS,
who showed much lower odds than those with AA in both ethnic
groups. In the overall population, with adjustment for ethnicity
and age, we indeed observed a 70% reduction in the odds of in-
fection for carriers of HbS (OR, 0.27; 95% CI, .11–.66; P = .004).
In the non-Fulani group, we could also observe that individ-
uals with CC or SC genotypes show lower odds of infection than
those with AA, although the comparison reaches statistical sig-
niﬁcance only for SC. It must be noted that these genotype
groups are very small. If we combine CC and SC genotypes in
a unique group of individuals with double-mutant hemoglobin,
these show >90% reduction in the odds of infection (OR for
CC + SC vs AA, 0.04; 95% CI, .01–.29; P = .002). It seems there-
fore that HbS is sufﬁcient in single copy to protect from infec-
tion, whereas HbC must be associated with either another copy
of HbC or with HbS for protection to be achieved. This is sim-
ilar to what was observed with respect to the protection con-
ferred against severe malaria, where HbC has an additive
effect, and individuals with the CC genotype show a much high-
er degree of protection than those with AC [2].
It is also interesting to note that the protection seen with AS,
CC, and SC genotypes in the non-Fulani group brings the odds
of infection to levels comparable to that of individuals with
wild-type AA in the Fulani group. The observation that the
odds of infection is lower in the Fulani for any HBB genotype,
together with the observation that HbS and HbC are present at
comparable and lower frequencies, respectively, further con-
ﬁrms that mutant hemoglobins are not responsible for the
lower susceptibility to malaria observed in this ethnic group
[44]. Comparable results were obtained applying a standard re-
peated measure approach, using data from the 5 surveys and a
mixed logistic regression model including a random effect de-
scribing the statistical dependency between measurements from
the same individual (Supplementary Table 1).
In the same group of subjects, we also looked at the number of
infections measured over 5 surveys according to HBB genotype
(data not shown). We observed that the numbers of infections are
comparable for subjects with AC and those with AA in both
Fulani and non-Fulani groups and in the overall population
Table 4. Proportion of Subjects Infected With Plasmodium falciparum at Least Once Over 5 Surveys According to HBB Genotype and
Statistical Comparison
HBB Genotype by Ethnicity
Subjects, No.a
OR (95% CI)b P ValuecP. falciparum Negative P. falciparum Positive P. falciparum Positive , %
Fulani
AA 49 97 66.4 . . . . . .
AC 9 14 60.9 1.13 (.36–3.58) .83
AS 11 6 35.3 0.32 (.09–1.06) .06
Non-Fulani
AA 21 181 89.6 . . . . . .
AC 6 63 91.3 1.8 (.62–5.22) .28
AS 6 12 66.7 0.24 (.07–.82) .02
CC 1 1 50 0.11 (.00–3.40) .21
SC 2 1 33.3 0.02 (.00–.28) .003
Abbreviations: CI, confidence interval; OR, odds ratio.
a The P. falciparum–negative group includes subjects not infected with P. falciparum over 5 cross-sectional surveys; the P. falciparum–positive group, subjects
infected with P. falciparum at least once over 5 cross-sectional surveys.
b ORs were adjusted for age group and ethnicity.
c P values based on logistic regression for the statistical comparison of odds, where the wild-type AA genotype is used as the reference group.
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(incidence rate ratio [IRR], 1.08; 95% CI, .92–1.27; P = .33). How-
ever, the numbers of infections are lower for AS than for AA in
both ethnic groups, although this difference reached statistical sig-
niﬁcance only in the overall population (IRR, 0.72; 95% CI, .53–.98;
P = .04). In the non-Fulani group, there was a nonsigniﬁcant reduc-
tion in the number of infections with the CC (IRR, 0.46; 95% CI,
.11–1.85; P = .27) and SC (IRR, 0.48; 95% CI, .18–1.28; P = .14) ge-
notypes and also when the 2 genotypes are grouped (IRR, 0.47;
95% CI, .21–1.06; P = .07).
Finally, we compared the mean parasite density observed
during the 5 surveys (ie, the mean of 5 trophozoite counts)
among HBB genotypes (data not shown). In both study popu-
lations, no difference in mean parasite density (log-transformed
parasite count per microliter) was observed between AC and
AA genotypes (OR, 1.07; 95% CI, .91–1.25; P = .42 in the overall
population). A nonsigniﬁcant reduction in mean parasite den-
sity was observed in both Fulani and non-Fulani groups when
comparing AS and AA genotypes, and this difference reached
statistical signiﬁcance in the overall population (OR, 0.78;
95% CI, .62–.99; P = .04). A reduction was observed among
the non-Fulani for the CC (OR, 0.48; 95% CI, .18–1.27;
P = .14) and SC (OR, 0.39; 95% CI, .18–.87; P = .02) genotypes,
although the difference was signiﬁcant only for SC. A signiﬁcant
protective effect was observed in the combined group of double-
mutant individuals (OR, 0.43; 95% CI, .23–.79; P = .007).
Survival Analysis of Repeated Cross-sectional Data: Proportion
of Subjects Who Remain P. falciparum Negative
We ﬁnally investigated whether HbS and HbC affect the pro-
portion of subjects who remain uninfected over surveys. We
included in this analysis all individuals present at the ﬁrst survey
(n = 1163) and followed them up until the end of the study,
looking at the ﬁrst time they became infected or whether they
stayed clear of infection.
The lifetime table resulting from this analysis is shown in
Supplementary Table 2. Because only the ﬁrst survey contribut-
ed information for subjects with CC and SC genotypes, we ex-
cluded these individuals from statistical analysis. Survival curves
for subjectsAA,AC, andAS genotypes are shown in Figure 1, and
the results of the log-rank test in Table 5. In both Fulani
(n = 401) and non-Fulani (n = 761) groups, we observed that
the proportion of individuals with the AC genotype who remain
uninfected is always comparable to that of those with AA (haz-
ard ratio, 1.02; 95% CI, .86–1.23; P = .75 in the overall popula-
tion with adjustment for ethnicity and age). On the contrary the
proportion of uninfected individuals is always higher for AS
than for AA. In the overall population, subjects carrying the HbS
mutation show a lower cumulative probability of becoming in-
fected (hazard ratio, 0.68; 95% CI, .47–.97; P = .03 with adjust-
ment for ethnicity and age). Similar results have been obtained
in longitudinal studies conducted in Uganda [35] and Mali [36].
Modiﬁcation of HbS Protective Effect by Age Group and
Ethnicity
Gong and colleagues [35] observed in their study that the pro-
tective effect of HbS increased with age. We therefore stratiﬁed
our sample into subjects aged ≤10 years and those aged >10
years to investigate whether age modiﬁes the effect of HbS on
the odds of infection, number of infections, mean parasite
count, and cumulative probability of infection (Supplementary
Figure 1. Lifetime curves showing proportions of individuals who remain uninfected with Plasmodium falciparum across 5 cross-sectional surveys, ac-
cording to HBB genotype; results are displayed separately for Fulani (right) and non-Fulani (left) groups.
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Table 3). For each phenotype analyzed, we observed no protec-
tive effect of HbS in the younger group but a signiﬁcant effect in
the older group. We also observed that in subjects aged >10
years the protective effect of HbS (except with respect to
mean parasite counts) seemed greater in the Fulani than in
the non-Fulani group, although there is no statistical evidence
of effect modiﬁcation (data not shown).
DISCUSSION
This study was intended to elucidate the role of HbS and HbC in
susceptibility to P. falciparum infection. One important chal-
lenge encountered in such studies is deﬁning an infection phe-
notype for association analysis. Indeed, the point prevalence of
P. falciparum parasitemia might not be a robust phenotype, be-
cause it can vary with both measurement and epidemiological
factors. Other phenotypes might prove more useful, such as the
odds of infection, the number of infections, the mean parasite
density over repeated measurements, and the proportion of sub-
ject who remain clear of infection over time. These can be based
on a series of cross-sectional surveys, as in our study, or, better,
from cohort studies.
We actually observed that individuals who are heterozygotes for
HbS show lower prevalences of parasitemia than AA homozygotes
in some but not every survey, and not always in both study pop-
ulations. This observation reﬂects discrepancies among results of
studies based on single cross-sectional surveys [16]. In longitudi-
nal analysis, however, AS heterozygotes show lower odds of infec-
tion than AA homozygotes, fewer infections, lower mean parasite
density, and a higher proportion of subjects who remain clear of
infection over time, in both Fulani and non-Fulani groups, sug-
gesting a protective role of HbS against the establishment of P. fal-
ciparum parasitemia. These results are consistent with those
obtained by Billo and colleagues [36], who observed that a protec-
tive role of HbS against infection could be observed only when the
data were analyzed longitudinally and not when the same data
were analyzed using a cross-sectional approach.
By stratifying the sample by age group, we were able to ob-
serve that the protective effect of HbS becomes apparent in sub-
jects aged >10 years, consistently with a recent report by Gong
and colleagues [35]. Furthermore, this protective effect is greater
in the less susceptible and more immune reactive Fulani popu-
lation [39, 45]. These 2 observations suggest that the role of HbS
is magniﬁed by concomitant immunity of the host. The fact that
the effect of HbS is greater at older ages could also indicate, as
suggested elsewhere [35], that the mechanism of protection in-
volves acquired immunity. However, because the Fulani are less
susceptible to infection on a different genetic basis than HbS,
the fact that the effect of HbS is greater in this ethnic group sug-
gests that the mechanism of protection is ampliﬁed by, and not
only mediated by, the host immune response, either innate or
acquired.
With respect to HbC, our data do not provide evidence for
protection against any of the phenotypes analyzed at the het-
erozygote state. Nevertheless, they suggest a protective effect of
HbC in a double-mutant state, that is, in CC homozygotes and
SC double heterozygotes. The level of protection observed is
similar if not higher to that observed in subjects with the AS
genotype. However, given the low frequencies of these geno-
types (<1%), our study sample size is too small to draw solid
conclusions.
Our results suggest a scenario made of consistent experimen-
tal and epidemiological observations. The abnormal display of
parasite-adhesive molecules (ie, PfEMP1) on the surface of the
HbS and HbC infected erythrocytes [46, 47], disrupting the
pathogenic process of sequestration, might displace the para-
site from the deep to the peripheral circulation, hence promot-
ing its elimination at the spleen level. It has been proposed
[48] that the increased phagocytosis of the HbS and HbC in-
fected erythrocytes in the spleen may also result in improved
antigen presentation, which could explain an increase of the
protective effect against infection with age, as well as the high-
er immune response to variant surface antigens observed in
individuals carrying those hemoglobinopathies [13, 49, 50].
A protective role of HbS and HbC against infection per se
is coherent with the observation that both mutant hemoglo-
bins protect against all syndromes of severe malaria (namely,
cerebral malaria and severe malarial anemia) across diverse
populations [8, 16].
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases
online (http://jid.oxfordjournals.org). Supplementary materials consist of
data provided by the author that are published to beneﬁt the reader. The
posted materials are not copyedited. The contents of all supplementary
data are the sole responsibility of the authors. Questions or messages regard-
ing errors should be addressed to the author.
Table 5. Statistical Comparison of Survival Curves According to
HBB Genotype
HBB Genotype
by Ethnicity
Infections
Observed, No.
Infections
Expected, No.
P
Valuea
Fulani
AA 159 152.1 . . .
AC 29 29.2 .66
AS 12 18.9 .047
Non-Fulani
AA 391 381.8 . . .
AC 121 121.6 .93
AS 20 29.2 .02
a P valueswere determinedwith the log-rank test for equality of survival curves,
with the wild-type AA genotype used as the reference group.
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